The aim of this study was to evaluate the association between postural orthostatic tachycardia syndrome (POTS) and circulating antiganglionic acetylcholine receptor (gAChR) antibodies. We reviewed clinical assessments of Japanese patients with POTS, and determined the presence of gAChR antibodies in serum samples from those patients. Luciferase immunoprecipitation systems detected anti-gAChRa3 and b4 antibodies in the sera from POTS (29%). Antecedent infections were frequently reported in patients in POTS patients. Moreover, autoimmune markers and comorbid autoimmune diseases were also frequent in seropositive POTS patients. Anti-gAChR antibodies were detectable in significant number of patients with POTS, and POTS entailed the element of autoimmune basis.
Introduction
Orthostasis and fatigue with autonomic dysfunction frequently occur in autoimmune diseases. 1 Postural orthostatic tachycardia syndrome (POTS) is the most common form of orthostatic intolerance characterized by lightheadedness, presyncope and palpitations, and nonorthostatic symptoms, such as fatigue, abnormalities of sleep, myofascial pain, nausea, and migraine headache. 2 Gastrointestinal (GI) disturbances are common and prolonged in patients with POTS, and it remains unknown whether extravascular volume depletion and deconditioning contribute to POTS in patients with other autonomic symptoms. 3, 4 The pathophysiology of POTS is heterogeneous and includes impaired sympathetically-mediated vasoconstriction, excessive sympathetic drive, volume dysregulation, and deconditioning. 2 An autoimmune basis has been suggested as a causal mechanism of POTS, and several autoreactive IgGs have been identified, including ganglionic acetylcholine receptor (gAChR), voltage-gated potassium channel complex, cardiac lipid raft-associated proteins, a1-adrenergic receptor, as well as b1-and b2-adrenergic receptors. [5] [6] [7] Moreover, Blitshteyn recently determined the high prevalence of positive ANA and other autoantibodies and the high prevalence of comorbid autoimmune disorders that exist in patients with POTS. 8, 9 Sandroni and Low demonstrated occasional positivity to gAChR antibodies in POTS patients. 10 Previously, we reported the relationship among the anti-gAChR antibodies, autonomic This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. dysfunction, and autoimmune rheumatic diseases. [11] [12] [13] We attempted to elucidate the autoimmune pathophysiology of POTS in this study as a part of our comprehensive approach. Therefore, we assessed the frequency of autonomic dysfunction in the patients with two highly prevalent orthostatic intolerances of POTS and neurally mediated syncope (NMS) using objective clinical indicators. And, we examined potential immune-mediation of POTS by evaluating autoantibodies against gAChR, which have been implicated in both POTS and POTS-associated autonomic dysfunction.
Patients and Methods
Standard protocol approvals, registrations, and patient consents All participants provided written informed consent. The Ethics Committee of Nagasaki Kawatana Medical Center and Kumamoto University Hospital approved the study.
Study design
First analysis (Fig. 1A) tested for the presence of gAChR antibodies in serum samples from 34 patients with POTS, 19 patients with NMS, 34 patients with OND, and 73 healthy controls. The diagnosis of POTS and NMS were confirmed using the consensus statement by the American Autonomic Society, the European Federation of Autonomic Societies, the Autonomic Research Group of the World Federation of Neurology and the Autonomic Disorders section of the American Academy of Neurology, and 2015 heart rhythm society expert consensus statement. [14] [15] [16] We compared the frequencies of autoantibodies against gAChR among four groups, and analyzed the clinical features between the POTS group and NMS group.
In second analysis (Fig. 1A) , we analyzed the clinical features between the seropositive and seronegative POTS group. 
Study population

years).
Luciferase immunoprecipitation system assay for autoantibodies against gAChR Serum gAChRa3 and b4 antibodies were detected using Luciferase immunoprecipitation system (LIPS) assays, as described previously.
11 Antibody levels were expressed as the antibody index (A.I.). We established a normalized value for HC as <1.000 A.I. To evaluate the diagnostic accuracy of this assay, we verified the cut-off points for all data collected in the previous study.
12,13
Clinical assessment of autonomic function
Comprehensive clinical, neurological, and serologic assessments were performed for all patients. We queried the presence or absence of each of the following functions that are controlled by the autonomic system as reported in our previous study: syncope or orthostatic hypotension (OH) for orthostatic intolerance (OI); arrhythmia; pupillary dysfunction; sicca complex; coughing episodes; skin dryness or hypohidrosis/anhidrosis for heat intolerance; upper GI system problems; diarrhea or constipation indicating dysfunction of the lower GI system; dysuria or urinary retention needing catheterization for bladder dysfunction; and sexual dysfunction. 11 For the all patients, questionnaires were sent to the referring neurologists.
Statistical analyses
SigmaPlot â was used for data analyses. The normally distributed A.I. data were analyzed by one-way analysis of variance between HC, POTS, NMS, and OND groups.
Frequencies of autoantibodies and non-normally distributed data were analyzed by one-way analyses of variance of ranks. For all analyses, P < 0.05 was considered statistically significant.
Results
Frequencies of autoantibodies against gAChR in first analysis
Using the LIPS assay, we found that 29% (10 of 34) of patients with POTS were positive for autoantibodies. Specifically, anti-gAChRa3 antibodies were detected in 8 samples (24%), and anti-gAChRb4 antibodies were detected in two samples (6%). Furthermore, no samples from the seropositive patients with POTS were positive for both antibodies. In contrast, we found that only one patient (5%) with NMS was positive for autoantibodies against gAChRa3. The frequencies of gAChRa3 antibodies in patients with POTS were statistically higher than those in patients with NMS (P = 0.041). However, no statistically significant difference was detected in between the POTS group and NMS group on the prevalence of antigAChR antibodies (P = 0.479). In all 73 HC, antigAChRa3 and anti-gAChRb4 antibodies were absent, and anti-gAChRa3 antibodies were detected in the serum of one patient in the OND group, who had suspected amyloid neuropathy (Fig. 1B) . The mean A.I. value for anti-gAChRa3 antibodies in the POTS group was 0.746, which was significantly greater than those obtained for the HC (0.305) or OND (0.336) groups (P < 0.001). The mean A.I. for antigAChRb4 antibodies in the POTS group was 0.536, which was also significantly greater than those obtained for the HC (0.367) or OND (0.302) groups (P = 0.007) (Fig. 1B) . However, the mean A.I. value for antigAChRa3 antibodies in the NMS group was 0.638, and the mean A.I. for anti-gAChRb4 antibodies in the NMS group was 0.421. No statistically significant difference was seen in between the POTS group and NMS group on the mean A.I. for anti-gAChRa3 and gAChRb4 antibodies (P = 0.774 and 0.744, respectively). Subacute onset was defined as the reaching of the peak of autonomic failure within 3 months, and chronic was defined as reaching of the peak after 3 months. 2 Mycoplasma pneumonia; four patients of flu-like symptom (fever, throat, and joint pain); three patients of upper respiratory tract (URT) infection; gastroenteritis; trauma. 3 Orthostatic intolerance = orthostatic hypotension and/or palpitation and/or syncope. 4 Upper gastrointestinal tract symptoms = appetite loss and/or nausea and/or vomiting and/or early satiety and/or postprandial abdominal pain. 5 Lower gastrointestinal tract symptoms = constipation and/or diarrhea and/or ileus. 6 Four patients of Amenorrhea. 7 Three patients of antinuclear antibody positive; two patients of Graves' disease; Sj€ ogren's syndrome; allergic bronchitis; rheumatoid arthritis and fibromyalgia. and age at onset in the patients with POTS were significantly younger than those in the patients with NMS (P = 0.004 and 0.013, respectively). Antecedent infections were reported in 10 patients (29%) in POTS group, and there was a difference between POTS group and NMS group (P = 0.010). Female was more frequently suffered in POTS group (24 patients, 71%) than in NMS group (7 patients, 37%) (P = 0.018).
Clinical assessment of autonomic function in patients with POTS and NMS in first analysis
Clinical assessment of autonomic function in patients with seropositive POTS in second analysis Table 2 summarizes the clinical characteristics and autonomic symptoms of patients with POTS, according to seroreactivity to anti-gAChR antibodies. The age in seropositive POTS group was significantly higher than those in seronegative POTS group (P = 0.012). As for the age at onset, similar trend was observed, but we found no statistical significance (P = 0.052). Antecedent infections were reported in five patients (50%) with seropositive POTS, but there were no differences between seropositive and seronegative patients. For autonomic symptoms, pupil abnormality and lower gastrointestinal tract symptoms were most frequently observed (P = 0.029 and 0.032, respectively). Other autoimmune diseases were more common in anti-gAChR antibody-positive patients than in those who were antibody-negative (P < 0.001). Three of 10 patients in the group of seropositive POTS were treated with intravenous methylprednisolone (IVMP) and resulted in clinical improvements. In the group of seronegative POTS, four of 24 patients were treated with IVMP. Three patients maintained improvements in OI, however, we found no clinical improvement in one patient.
Discussion
In this study, we assessed presence or absence of autoantibodies against gAChR in patients with POTS and NMS. We found that anti-gAChR antibodies were detected more frequently in patients with POTS compared to NMS and controls, suggesting that anti-gAChR antibodies may be associated with POTS and its underlying autonomic dysfunction. POTS and NMS were clearly distinguishable by the prevalence of anti-gAChR antibodies. On the basis of the acknowledgment, we verified widespread autonomic manifestations based on neurological assessments, and identified other autoimmune complications in POTS patients with seropositive for anti-gAChR antibodies. Trauma; gastroenteritis; flu-like symptom (fever, throat, and joint pain); Two patients of URT infection. 3 Amenorrhea. 4 Amenorrhea. 5 Three patients of antinuclear antibody positive; Graves' disease; Sj€ ogren's syndrome; rheumatoid arthritis; and fibromyalgia. 6 Graves' disease; allergic bronchitis.
However, the majority of seropositive samples did not have high levels of autoantibodies for gAChR. Therefore, elevated expression of antibodies to gAChR subunits may contribute to secondary autoimmune responses to ganglionic neuron damage in seropositive patients. The prevalence of anti-gAChR antibodies in this study was higher than that in previous study. 17 Anti-gAChR antibodies may impair autonomic ganglionic synaptic transmission, and antibodies that interfere with ganglionic transmission may contribute to dysautonomia in patients with POTS. 18 Although POTS is pathophysiologically categorized into four subtypes (neuropathic, hyperadrenergic, volume dysregulation, and physical deconditioning), it is not clear which subtype corresponds to gAChR autoimmunity-related POTS, or whether anti-gAChR antibodies have stimulatory functions that produce overactivity of sympathetic ganglia (i.e., type V hypersensitivity).
2 Although POTS is a heterogeneous syndrome with various pathophysiologic mechanisms and complex symptomatology, we demonstrated POTS patients with autoimmune basis were present in significant proportions. 2 In addition, we noted the possibility that antigAChR antibodies are associated with autonomic dysfunction (e.g., POTS) in autoimmune rheumatic diseases. 12, 13 This study is limited by an observational design and small sample size. Therefore, a subsequent study will be conducted in order to confirm the potential for immunotherapy to resolve the symptoms of autoimmune POTS and associated autonomic effects. A prospective, multicenter, clinical interventional study is necessary in order to confirm the relationships between levels of antigAChR antibodies and the severity of POTS and autonomic symptoms.
In conclusion, we could demonstrate that the antigAChR antibodies were detected more frequently in patients with POTS compared to NMS and controls. Seropositive POTS patients demonstrated autoimmune markers and comorbid autoimmune diseases were frequent. The results have important implications for our understanding of the pathophysiology of POTS and for the interpretation of humoral antibody responses in POTS.
